anti-PDI mAb pembrolizumab
Merck has recently opened several clinical trials using the anti-PDI mAb pembrolizumab which may be of interest for individuals who have developed advanced stage cancers. These trials are enrolling patients with tumors that are microsatellite instability-high (MSI-H). For those with advanced stage MSI-H colorectal cancer...
18 July, 2016